<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Cardiology Product Guide &#187; cardiovascular events</title>
	<atom:link href="http://www.cardiologyproductguide.com/blog/tag/cardiovascular-events/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.cardiologyproductguide.com/blog</link>
	<description>A comprehensive guide to cardiology products for medical professionals</description>
	<lastBuildDate>Tue, 07 Sep 2010 07:46:42 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Telmisartan helps in reducing cardiovascular risk</title>
		<link>http://www.cardiologyproductguide.com/blog/2008/09/02/telmisartan-helps-in-reducing-cardiovascular-risk/</link>
		<comments>http://www.cardiologyproductguide.com/blog/2008/09/02/telmisartan-helps-in-reducing-cardiovascular-risk/#comments</comments>
		<pubDate>Tue, 02 Sep 2008 18:35:43 +0000</pubDate>
		<dc:creator>Jim Marino</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[ACE inhibitors]]></category>
		<category><![CDATA[cardiovascular events]]></category>
		<category><![CDATA[Hamilton Health Sciences]]></category>
		<category><![CDATA[telmisartan]]></category>

		<guid isPermaLink="false">http://www.cardiologyproductguide.com/blog/2008/09/02/telmisartan-helps-in-reducing-cardiovascular-risk/</guid>
		<description><![CDATA[The TRANSCEND study authored by Dr Salim Yusuf, Hamilton Health Sciences and McMaster University, Hamilton (Ontario, Canada) concluded that the angiotensin-receptor blocker (ARB) telmisartan, when added to other reliable therapies,  proves to be of an additional advantage in treating patients who are unable to tolerate the standard treatment of angiotensin-converting enzyme (ACE) inhibitors. The researchers [...]]]></description>
			<content:encoded><![CDATA[<p><img vspace="5" align="left" width="200" src="http://www.cardiologyproductguide.com/blog/wp-content/uploads/2008/09/hamilton-health-sc.png" hspace="5" height="109" />The TRANSCEND study authored by Dr Salim Yusuf, <a href="http://www.hamiltonhealthsciences.ca/">Hamilton Health Sciences and McMaster University</a>, Hamilton (Ontario, Canada) concluded that the angiotensin-receptor blocker (ARB) telmisartan, when added to other reliable therapies,  proves to be of an additional advantage in treating patients who are unable to tolerate the standard treatment of angiotensin-converting enzyme (ACE) inhibitors. The researchers found in a trial that mean blood pressure was lower in the patients given a dose of telmisartan. Major adverse cardiovascular events such as death, heart attack or stroke were 13% less likely in telmisartan patients as against the placebo group.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.cardiologyproductguide.com/blog/2008/09/02/telmisartan-helps-in-reducing-cardiovascular-risk/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
	</channel>
</rss>
